BioSpace News Archive

Otonomy, Inc. today provided an update on its product pipeline and financial guidance.

Sensei Biotherapeutics, Inc., an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced two key promotions within the company’s senior management team.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces receipt of guidance from the U.S. Food and Drug Administration (FDA) for the further development of CDI-45205, Cocrystal’s novel SARS-CoV-2 main protease inhibitor as a potential treatment for COVID-19 and its variants via intranasal/pulmonary delivery.

Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 2:00 p.m. EST.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced certain preliminary, unaudited financial results for the year ended December 31, 2021.

Xilio Therapeutics, Inc. today announced the appointment of Yuan Xu, Ph.D., to its board of directors.

KemPharm, Inc. announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.

Intellia Therapeutics, Inc. today outlined its expected milestones and the following strategic priorities for 2022.

Alterity Therapeutics today announced the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,155,547) to Alterity.

The RD Fund announces its participation in $115 million syndicated Series B round for SalioGen Therapeutics to support the company’s preclinical research into novel genetic medicines for inherited retinal disorders.